Poorer and less-educated older Americans are more likely to suffer from chronic pain than those with greater wealth and more education, but the disparity between the two groups is much greater than previously thought, according to new research.
All News
Patients known to be autoantibody positive (e.g., anti- Jo1) for the anti-synthetase syndrome were assayed by indirect immunofluorescence (IIF) for other reactivities, showing antinuclear staining (ANA) or cytoplasmic staining (Anti-Cyt Ab+).
Oligoarticular-onset juvenile idiopathic arthritis accounts for nearly half of all JIA patients. While many of these children will require DMARD therapy, many others are treated with antiinflammatory meds or intra-articular corticosteroids. But the evidence for this latter approach is scant.
US and UK researchers have identified a unique subset of helper T-cells called ‘peripheral helper’ T-cells in the synoviums that may be linked to the pathogenesis of rheumatoid arthritis.
The George Institute for Global Health has performed a systematic review of drugs used to treat back pain. Their findings, published in the Annals of the Rheumatic Diseases, shows that only one in six improve their pain with NSAID therapy.
Up to 30% of patients with rheumatoid arthritis (RA) will eventually undergo joint reconstructive surgery, yet we have limited data to guide the perioperative management of DMARDs and biologics.
Doubt remains regarding the appropriateness, efficacy and safety of methotrexate in the treatment of moderate to severe cutaneous psoriasis. Moreover, high dose, subcutaneous MTX has not been studied in a well-designed trial.
Dr. Jack Cush reviews this week's highlights from RheumNow.
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
Gout should be one of the easiest and best managed of rheumatic disorders. However, numerous deficits exist with regard to the treatment and long-term care of gout.
Prior to the biologic era, nonsteroidal antiinflammatory drugs (NSAIDs) were the mainstay of drug therapy in thos with spondyloarthritis (SpA) and ankylosing spondylitis (AS). Their role in the modern era has changed and the claims for efficacy have varied.
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Most patients who present with gout to rheumatology clinics are at very high risk of cardiovascular (CV) disease, Spanish researchers found.
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Infection is a major cause of morbidity and mortality in RA patients and thus vaccinating against preventable infections is a top priority for rheumatologists.
Dr. Cush reviews highlights from the past week on RheumNow.com.
A JAMA article presents the US Public Health Task Force review of OSA testing.
Neuropsychiatric lupus (NPSLE) is a diagnostic challenge as its clinical manifestations are protean and the pathophysiology is poorly understood.
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Researchers from the Massachusetts General Hospital (MGH) have studied the initial steps in an animal model of inflammatory arthritis and found that complement C5a is critical to neutrophils migration into joints.
